Vitiligo - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Vitiligo - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Vitiligo: Overview
Vitiligo is a complex pigment disorder that involves the skin, the hair, and occasionally the mucous membranes. It is a long-term condition where pale white patches develop on the skin. Vitiligo can affect any area of skin, but it commonly happens on the face, neck and hands. Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. The diagnosis of vitiligo is primarily made on clinical grounds and is based on history, clinical presentation, and family history (vitiligo, autoimmune disorders). The most extensively characterized clinical markers of active, progressive disease include: Koebner’s phenomenon, trichrome lesions, inflammatory lesions and confetti-like depigmentation. The optimal treatment of vitiligo will depend on the subtype of the disease, percent of body surface area (BSA) involved, effect on quality of life, and the perception of the patient concerning the risk to benefit ratio. These treatments include phototherapy, topical and systemic immunosuppressants, and surgical techniques, stabilizing depigmented lesions and stimulating repigmentation.
'Vitiligo - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vitiligo pipeline landscape is provided which includes the disease overview and Vitiligo treatment guidelines. The assessment part of the report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Vitiligo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vitiligo Emerging Drugs
Further product details are provided in the repor
Vitiligo: Therapeutic Assessment
This segment of the report provides insights about the different Vitiligo drugs segregated based on following parameters that define the scope of the report, such as:
Vitiligo: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vitiligo therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vitiligo drugs.
Vitiligo Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Vitiligo - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Vitiligo: Overview
Vitiligo is a complex pigment disorder that involves the skin, the hair, and occasionally the mucous membranes. It is a long-term condition where pale white patches develop on the skin. Vitiligo can affect any area of skin, but it commonly happens on the face, neck and hands. Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. The diagnosis of vitiligo is primarily made on clinical grounds and is based on history, clinical presentation, and family history (vitiligo, autoimmune disorders). The most extensively characterized clinical markers of active, progressive disease include: Koebner’s phenomenon, trichrome lesions, inflammatory lesions and confetti-like depigmentation. The optimal treatment of vitiligo will depend on the subtype of the disease, percent of body surface area (BSA) involved, effect on quality of life, and the perception of the patient concerning the risk to benefit ratio. These treatments include phototherapy, topical and systemic immunosuppressants, and surgical techniques, stabilizing depigmented lesions and stimulating repigmentation.
'Vitiligo - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vitiligo pipeline landscape is provided which includes the disease overview and Vitiligo treatment guidelines. The assessment part of the report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The therapies under development are focused on novel approaches to treat/improve Vitiligo.
- In September 2020, TAGCyx biotechnologies entered into a research collaboration with CAGE Bio for development of TAGX-0003 for treatment of dermatological autoimmune skin diseases. TAGX-0003 is a DNA aptamer possessing potent IFN-?antagonistic activity developed by TAGCyx and has already shown effective data in humanized autoimmune skin disease animal model such as alopecia areata when intra-dermally injected.
This segment of the Vitiligo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vitiligo Emerging Drugs
- Ruxolitinib: Incyte Corporation
- PF-06651600: Pfizer
Further product details are provided in the repor
Vitiligo: Therapeutic Assessment
This segment of the report provides insights about the different Vitiligo drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vitiligo
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Vitiligo: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vitiligo therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vitiligo drugs.
Vitiligo Report Insights
- Vitiligo Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vitiligo drugs?
- How many Vitiligo drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vitiligo?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vitiligo therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vitiligo and their status?
- What are the key designations that have been granted to the emerging drugs?
- Incyte Corporation
- Amgen
- Boston Pharmaceuticals
- Arcutis Biotherapeutics
- Pfizer
- Dermavant Sciences
- Clinuvel Pharmaceuticals
- Celgene
- TWi Biotechnology
- AXIM Biotechnologies
- Arrien Pharmaceuticals
- Dermira
- Ruxolitinib
- AMG-714
- BOS 475
- ARQ-252
- PF-06651600
- Cerdulatinib
- Afamelanotide
- Apremilast
- AC-1101
- AX 1602
- ARN-4079
- QLT-450
Introduction
Executive Summary
Vitiligo: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vitiligo – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vitiligo companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vitiligo Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ruxolitinib: Incyte Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
PF-06651600: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AC-1101: TWi Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
QLT-450: Dermira
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vitiligo Key Companies
Vitiligo Key Products
Vitiligo- Unmet Needs
Vitiligo- Market Drivers and Barriers
Vitiligo- Future Perspectives and Conclusion
Vitiligo Analyst Views
Vitiligo Key Companies
Appendix
Executive Summary
Vitiligo: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Vitiligo – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Vitiligo companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Vitiligo Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Ruxolitinib: Incyte Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
PF-06651600: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AC-1101: TWi Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
QLT-450: Dermira
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Vitiligo Key Companies
Vitiligo Key Products
Vitiligo- Unmet Needs
Vitiligo- Market Drivers and Barriers
Vitiligo- Future Perspectives and Conclusion
Vitiligo Analyst Views
Vitiligo Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Vitiligo
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Vitiligo
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Vitiligo
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Vitiligo
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products